当前位置: 首页 >> 检索结果
533. Risk of Active Tuberculosis in the Five Years Following Infection . . . 15%?
作者: James M Trauer.;Nompilo Moyo.;Ee-Laine Tay.;Katie Dale.;Romain Ragonnet.;Emma S McBryde.;Justin T Denholm.
来源: Chest. 2016年149卷2期516-525页
It is often stated that the lifetime risk of developing active TB after an index infection is 5% to 10%, one-half of which accrues in the 2 to 5 years following infection. The goal of this study was to determine whether such estimates are consistent with local programmatic data.
534. Is Alveolar Macrophage Phagocytic Dysfunction in Children With Protracted Bacterial Bronchitis a Forerunner to Bronchiectasis?
作者: Sandra Hodge.;John W Upham.;Susan Pizzutto.;Helen L Petsky.;Stephanie Yerkovich.;Katherine J Baines.;Peter Gibson.;Jodie L Simpson.;Helen Buntain.;Alice C H Chen.;Greg Hodge.;Anne B Chang.
来源: Chest. 2016年149卷2期508-515页
Children with recurrent protracted bacterial bronchitis (PBB) and bronchiectasis share common features, and PBB is likely a forerunner to bronchiectasis. Both diseases are associated with neutrophilic inflammation and frequent isolation of potentially pathogenic microorganisms, including nontypeable Haemophilus influenzae (NTHi), from the lower airway. Defective alveolar macrophage phagocytosis of apoptotic bronchial epithelial cells (efferocytosis), as found in other chronic lung diseases, may also contribute to tissue damage and neutrophil persistence. Thus, in children with bronchiectasis or PBB and in control subjects, we quantified the phagocytosis of airway apoptotic cells and NTHi by alveolar macrophages and related the phagocytic capacity to clinical and airway inflammation.
535. Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score.
作者: David C Hostler.;Elizabeth S Marx.;Lisa K Moores.;Sarah K Petteys.;Jordanna Mae Hostler.;Joshua D Mitchell.;Paul R Holley.;Jacob F Collen.;Brian E Foster.;Aaron B Holley.
来源: Chest. 2016年149卷2期372-9页
Recent guidelines recommend assessing medical inpatients for bleeding risk prior to providing chemical prophylaxis for VTE. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) bleeding risk score (BRS) was derived from a well-defined population of medical inpatients but it has not been validated externally. We sought to externally validate the IMPROVE BRS.
536. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
作者: Clive Kearon.;Elie A Akl.;Joseph Ornelas.;Allen Blaivas.;David Jimenez.;Henri Bounameaux.;Menno Huisman.;Christopher S King.;Timothy A Morris.;Namita Sood.;Scott M Stevens.;Janine R E Vintch.;Philip Wells.;Scott C Woller.;Lisa Moores.
来源: Chest. 2016年149卷2期315-352页
We update recommendations on 12 topics that were in the 9th edition of these guidelines, and address 3 new topics.
|